Showing results (241-250 of 254) with videos related to

Sort By:
Pageof 26
Nature Communications|November 19, 2021
Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunityIrene A Abela, Chloé Pasin, Magdalena Schwarzmüller, et al.
Blood|January 5, 2017
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AMLBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Cell Host & Microbe|July 21, 2009
Humanized mice for modeling human infectious disease: challenges, progress, and outlookNicolas Legrand, Alexander Ploss, Rudi Balling, et al.
Life Science Alliance|June 25, 2020
EBV renders B cells susceptible to HIV-1 in humanized miceDonal McHugh, Renier Myburgh, Nicole Caduff, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Haematologica|April 30, 2025
Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, et al.
Nature Communications|October 31, 2024
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaRebekka Wegmann, Ximena Bonilla, Ruben Casanova, et al.
Cancer|April 7, 2018
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesionsKenneth L McClain, Jennifer Picarsic, Rikhia Chakraborty, et al.
Pageof 26